Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Agenus Inc AGEN

Healthcare Biotechnology
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its... see more

Recent & Breaking News (NDAQ:AGEN)

Agenus to Report Fourth Quarter and Year End 2016 Financial Results on March 9, 2017; Conference Call to Follow

PR Newswire March 2, 2017

New Cancer Therapeutics Drive the Cancer Biological Therapy Market

PR Newswire February 27, 2017

How These Biotech Stocks are Faring? -- Agenus, Tokai Pharma, Eleven Biotherapeutics, and Rexahn Pharma

PR Newswire February 14, 2017

Incyte and Agenus Amend Collaboration Agreement

Business Wire February 14, 2017

Agenus Appoints Jean-Marie Cuillerot, M.D. Chief Medical Officer

PR Newswire January 30, 2017

Agenus announces collaboration with the National Cancer Institute to evaluate the combination of Pembrolizumab (Keytruda®, Merck & Co., Inc.) with Prophage™ (Agenus Inc.) autologous vaccine

PR Newswire January 17, 2017

How These Biotech Stocks are Faring? -- Agenus, Kite Pharma, Ocular Therapeutix, and Radius Health

PR Newswire December 15, 2016

Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-OX40 Checkpoint Antibody INCAGN1949 in Patients with Solid Tumors

PR Newswire November 30, 2016

Agenus to Present at the Jefferies 2016 London Healthcare Conference

PR Newswire November 14, 2016

Biotech Stocks on Investors' Radar -- Agenus, Portola Pharma, Tobira Therapeutics, and Auris Medical

PR Newswire November 1, 2016

Agenus Reports Third Quarter Financial Results and Recent Highlights

PR Newswire October 27, 2016

Agenus to Report Third Quarter 2016 Financial Results on October 27, 2016; Conference Call to Follow

PR Newswire October 20, 2016

Agenus Appoints James Gorman, M.D., Ph.D. as Vice President of Strategic Planning and Portfolio Management

PR Newswire October 18, 2016

The Bioscience and Biotechnology Sector Developments in Cancer Therapy

PR Newswire September 26, 2016

Watch These 7 Huge Call Purchases In Friday Trade

Benzinga.com  August 12, 2016

Agenus Reports Second Quarter 2016 Financial Results and Operational Progress

Business Wire July 28, 2016

Agenus to Report Second Quarter 2016 Financial Results on July 28, 2016; Conference Call to Follow

Business Wire July 21, 2016

Agenus Appoints Jean-Marie Cuillerot, M.D. as Vice President and Global Head of Clinical Development

Business Wire July 6, 2016

Technical Coverage of Biotechnology Stocks - Agenus, BioCryst Pharma, Cempra, and Hemispherx Biopharma

PR Newswire June 30, 2016

Agenus Announces Commencement of Phase 1/2 Clinical Trial of anti-GITR Checkpoint Antibody INCAGN1876 in Patients with Solid Tumors

Business Wire June 22, 2016